Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
5-HT1A Partial Agonist
66%
5-HT1A Receptor Partial Agonist
100%
Adjunctive Therapy
66%
Antipsychotic Drugs
100%
Antipsychotics
16%
Azapirones
100%
Buspirone
16%
Cochrane Library
16%
Confidence Interval
100%
Controlled Clinical Trial
16%
Discontinuation Rate
16%
Drug Action
100%
Exclusion Criteria
16%
Google Scholar
16%
Meta-analysis
100%
Negative Symptoms
33%
No Significant Difference
16%
Patient numbers
16%
Patients with Schizophrenia
50%
Placebo
50%
Positive Symptoms
50%
Psychopathology Symptoms
16%
PsycINFO
16%
PubMed
16%
Randomized Placebo-controlled Trial
16%
Risk Ratio
50%
Serotonin-1A
16%
Standardized Mean Difference
66%
Systematic Literature Review
16%
Tandospirone
16%
Neuroscience
5-HT1A Receptor
100%
Adjuvant Therapy
75%
Agonist
100%
Antipsychotic
100%
Azapirone
100%
Buspirone
25%
Meta-Analysis
100%
Negative Syndrome
50%
Placebo
100%
Positive Syndrome
75%
Psychopathology
75%
Receptor Partial Agonist
100%
Schizophrenia
75%
Side Effect
25%
Systematic Review
25%
Tandospirone
25%
Medicine and Dentistry
5-HT1A Receptors
100%
Adjuvant Therapy
50%
Antipsychotic
100%
Azapirone
100%
Buspirone
16%
Controlled Clinical Trial
16%
Meta-Analysis
100%
Negative Syndrome
33%
Neurodevelopmental Disorder
50%
Partial Agonist
100%
Placebo
66%
Positive Syndrome
50%
Schizophrenia
50%
Side Effect
16%
Systematic Review
16%
Tandospirone
16%
Pharmacology, Toxicology and Pharmaceutical Science
Antipsychotic
100%
Azapirone
100%
Buspirone
16%
Controlled Clinical Trial
16%
Mental Diseases
50%
Negative Syndrome
33%
Partial Agonist
100%
Placebo
66%
Positive Syndrome
50%
Schizophrenia
50%
Side Effect
16%
Tandospirone
16%
Psychology
Clinical Trial
25%
Meta-Analysis
100%
Psychopathology
75%
Schizophrenia
75%
Standardized Mean Difference
100%
Systematic Review
25%
Immunology and Microbiology
Agonist
100%
Cochrane Library
16%
Drug Mechanism
100%
Medline
16%
PsycINFO
16%